Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Home Newsfeeds JMP Securities Maintains Market Outperform on Vacasa, Lowers Price Target to $3

JMP Securities Maintains Market Outperform on Vacasa, Lowers Price Target to $3

JMP Securities analyst Nicholas Jones maintains Vacasa (NASDAQ:VCSA) with a Market Outperform and lowers the price target from $5 to $3.

byBenzinga Newsdesk

December 20, 2022

1 minute read

JMP Securities analyst Nicholas Jones maintains Vacasa (NASDAQ:VCSA) with a Market Outperform and lowers the price target from $5 to $3.

European Authority Backs AbbVie’s Crohn’s Disease Candidate

By Vandana Singh

September 19, 9:43 AM

The European Medicines Agency’s Committee for Medicinal Products for Human Use has adopted a positive opinion recommending approval of AbbVie Inc’s (NYSE:ABBV)…

ABBV

Analyst Ratings

Evaluating Federated Hermes: Insights From 4 Financial Analysts

By Benzinga Insights

January 18, 4:00 PM

Across the recent three months, 4 analysts have shared their insights on Federated Hermes (NYSE:FHI), expressing a variety…

FHI

Analyst Ratings

Expert Ratings for Wendy’s

By Benzinga Insights

May 11, 8:05 AM

Over the past 3 months, 11 analysts have published their opinion on Wendy’s (NASDAQ:WEN) stock. These analysts are…

WEN

News

What’s Going On With Palantir Technologies (PLTR) Shares

By Henry Khederian

June 23, 10:11 AM

Palantir Technologies Inc (NYSE: PLTR) shares are trading lower by 18.50% to $13.77 over the trailing five sessions.

PLTR

JMP Securities Maintains Market Outperform on Vacasa, Lowers Price Target to $3

Related Posts

European Authority Backs AbbVie’s Crohn’s Disease Candidate

Evaluating Federated Hermes: Insights From 4 Financial Analysts

Expert Ratings for Wendy’s

What’s Going On With Palantir Technologies (PLTR) Shares